Blog
About

37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PDGFRA activating mutations in gastrointestinal stromal tumors.

      Science (New York, N.Y.)

      metabolism, Animals, CHO Cells, Chromosome Aberrations, Cricetinae, DNA-Binding Proteins, Enzyme Activation, Exons, Gastrointestinal Neoplasms, genetics, Humans, Karyotyping, Mitogen-Activated Protein Kinases, Mutation, Oncogenes, Phosphorylation, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-akt, Proto-Oncogene Proteins c-kit, Receptor, Platelet-Derived Growth Factor alpha, STAT1 Transcription Factor, STAT3 Transcription Factor, Signal Transduction, Trans-Activators

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most gastrointestinal stromal tumors (GISTs) have activating mutations in the KIT receptor tyrosine kinase, and most patients with GISTs respond well to Gleevec, which inhibits KIT kinase activity. Here we show that approximately 35% (14 of 40) of GISTs lacking KIT mutations have intragenic activation mutations in the related receptor tyrosine kinase, platelet-derived growth factor receptor alpha (PDGFRA). Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression. Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.

          Related collections

          Author and article information

          Journal
          12522257
          10.1126/science.1079666

          Comments

          Comment on this article